Hampel H, et al. - The researchers compared the diagnostic and classificatory performances of all combinations of novel and core cerebrospinal fluid candidates [amyloid β peptide (Aβ_1–42), total-tau, phosphorylated-tau, neurofilament light chain protein, neurogranin, and YKL-40] among individuals with mild cognitive impairment, Alzheimer's disease dementia (ADD), frontotemporal dementia (FTD), and cognitively healthy controls (HC). For the discrimination between ADD and FTD, these markers demonstrated at least fair accuracy. A poor classification was found of the mild cognitive impairment individuals.